Group One Trading’s Theravance Biopharma TBPH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $120K | Sell |
7,057
-6,068
| -46% | -$100K | ﹤0.01% | 4692 |
|
|
2026
Q1 | $213K | Buy |
13,125
+12,175
| +1,282% | +$215K | ﹤0.01% | 4059 |
|
|
2025
Q4 | $17.8K | Buy |
950
+634
| +201% | +$10.5K | ﹤0.01% | 6434 |
|
|
2025
Q3 | $4.61K | Buy |
+316
| New | +$3.99K | ﹤0.01% | 7584 |
|
|
2023
Q3 | – | Sell |
-3,069
| Closed | -$29.6K | – | 8290 |
|
|
2023
Q2 | $31.8K | Sell |
3,069
-543
| -15% | -$6K | ﹤0.01% | 5642 |
|
|
2023
Q1 | $39.2K | Buy |
+3,612
| New | +$38.2K | ﹤0.01% | 5033 |
|
|
2022
Q4 | – | Sell |
-3,608
| Closed | -$37.9K | – | 8068 |
|
|
2022
Q3 | $37K | Buy |
3,608
+1,933
| +115% | +$18.1K | ﹤0.01% | 5646 |
|
|
2022
Q2 | $15K | Sell |
1,675
-7,000
| -81% | -$64.5K | ﹤0.01% | 6521 |
|
|
2022
Q1 | $83K | Sell |
8,675
-36,330
| -81% | -$356K | ﹤0.01% | 5678 |
|
|
2021
Q4 | $497K | Sell |
45,005
-20,053
| -31% | -$175K | ﹤0.01% | 4139 |
|
|
2021
Q3 | $481K | Buy |
+65,058
| New | +$728K | ﹤0.01% | 4230 |
|
|
2020
Q1 | – | Sell |
-637
| Closed | -$15.9K | – | 5735 |
|
|
2019
Q4 | $16K | Sell |
637
-16,100
| -96% | -$313K | ﹤0.01% | 4444 |
|
|
2019
Q3 | $326K | Sell |
16,737
-42,831
| -72% | -$865K | ﹤0.01% | 2702 |
|
|
2019
Q2 | $973K | Buy |
59,568
+47,991
| +415% | +$972K | 0.01% | 1614 |
|
|
2019
Q1 | $262K | Buy |
+11,577
| New | +$294K | ﹤0.01% | 2496 |
|
|
2018
Q2 | – | Sell |
-1,100
| Closed | -$27K | – | 5463 |
|
|
2018
Q1 | $27K | Buy |
+1,100
| New | +$30.2K | ﹤0.01% | 3969 |
|
|
2017
Q4 | – | Sell |
-3,500
| Closed | -$120K | – | 5215 |
|
|
2017
Q3 | $120K | Buy |
+3,500
| New | +$114K | ﹤0.01% | 3114 |
|
|
2016
Q4 | – | Sell |
-1,377
| Closed | -$42.7K | – | 4834 |
|
|
2016
Q3 | $50K | Buy |
+1,377
| New | +$38.3K | ﹤0.01% | 3354 |
|
|
2016
Q2 | – | Sell |
-2,912
| Closed | -$62.9K | – | 4940 |
|
|
2016
Q1 | $55K | Sell |
2,912
-600
| -17% | -$9.82K | ﹤0.01% | 3207 |
|
|
2015
Q4 | $58K | Sell |
3,512
-43,772
| -93% | -$695K | ﹤0.01% | 3324 |
|
|
2015
Q3 | $520K | Buy |
+47,284
| New | +$602K | 0.01% | 1752 |
|
|
2015
Q2 | – | Sell |
-581
| Closed | -$9.01K | – | 5166 |
|
|
2015
Q1 | $10K | Buy |
+581
| New | +$10.7K | ﹤0.01% | 4146 |
|
|
2014
Q4 | – | Sell |
-2,093
| Closed | -$48K | – | 5257 |
|
|
2014
Q3 | $48K | Sell |
2,093
-1,428
| -41% | -$41.4K | ﹤0.01% | 3549 |
|
|
2014
Q2 | $112K | Buy |
+3,521
| New | +$106K | ﹤0.01% | 2877 |
|
Other funds holding TBPH
MAP
WAM
NM
ICM
Group One Trading's TBPH Position: Q2 2026 in Review
Group One Trading reduced its Theravance Biopharma (TBPH) stake by 46% in Q2 2026, selling an estimated $100K and leaving 7,057 shares worth $120K. The position accounts for ﹤0.01% of the portfolio, ranked #4692.
Group One Trading first reported a position in TBPH in Q2 2014 and has held it in 24 quarters since. The position peaked at $973K in Q2 2019. 180 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.
- Group One Trading held 7,057 shares of Theravance Biopharma worth $120K as of Q2 2026.
- Group One Trading sold 6,068 Theravance Biopharma shares in Q2 2026, an estimated $100K.
- Theravance Biopharma made up ﹤0.01% of Group One Trading's portfolio in Q2 2026, its #4692 holding.
- Group One Trading first reported a position in Theravance Biopharma in Q2 2014 and has held it in 24 quarters since.
- Group One Trading's Theravance Biopharma position peaked at $973K in Q2 2019.
- 180 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.
Based on Group One Trading's 13F filing for Q2 2026, filed 14 Aug 2026.